Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05525286 Suspended - Pancreatic Cancer Clinical Trials

Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma

CLAUDIO-01
Start date: March 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will assess the MTD and RP2D of SOT102 administered as monotherapy (Part A) and in combination with first-line SoC treatment (mFOLFOX6 with nivolumab and nab-paclitaxel/ gemcitabine; Part B) and efficacy of SOT102 administered as monotherapy (Part C) and in combination with first-line SoC treatment (Part D) in patients with advanced inoperable or metastatic gastric/GEJ adenocarcinoma or inoperable or metastatic pancreatic adenocarcinoma.

NCT ID: NCT05519930 Suspended - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Early Detection Registry

Start date: October 18, 2016
Phase:
Study type: Observational [Patient Registry]

Identify individuals who are at moderate and high risk or predisposed to developing pancreatic cancer with a familial history in which data collected from this study will be used to identify clinical factors associated with early detection of pancreatic cancer.

NCT ID: NCT04452357 Suspended - Pancreatic Cancer Clinical Trials

Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer

Start date: January 13, 2020
Phase: N/A
Study type: Interventional

Standard chemoradiation, followed by surgery are standard treatment plan for patients suffering from pancreatic adenocarcinoma. Due to damage to the surrounding healthy tissue caused by standard radiation, this study uses a new type of radiation plan- pulsed low-dose rate (PLDR) radiation , in combination with chemotherapeutic drug, gemcitabine, given weekly along with the radiation.

NCT ID: NCT03417921 Suspended - Pancreatic Cancer Clinical Trials

A Study of ABTL0812 in Pancreatic Cancer

Pancreatic
Start date: April 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy.

NCT ID: NCT00909558 Suspended - Breast Cancer Clinical Trials

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.

NCT ID: NCT00536770 Suspended - Pancreatic Cancer Clinical Trials

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

Start date: September 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.

NCT ID: NCT00209677 Suspended - Pancreatic Cancer Clinical Trials

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Start date: December 2004
Phase: Phase 1/Phase 2
Study type: Interventional

To assess the usefulness of Gemcitabine plus S-1 therapy based on the antitumor effect and survival period. By performing a phase I/II study of this combination in patients with inoperable or with postoperative pancreatic cancer.